ClinicalTrials.gg
CompletedNCT03885882Updated Dec 24, 2019

A Pharmacokinetic (PK) Study of Three Types of E0302 Sustained Release (SR) Tablets Compared With E0302 Immediate Release (IR) Tablet Under Fed Conditions in Healthy Participants

A Phase 1 interventional study of E0302 SR1 and E0302 SR3 in Healthy Subjects, sponsored by Eisai Co., Ltd.. Completed at 1 site in New Zealand. Open to participants aged 18 Years to 59 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-12-24.

Sponsored by Eisai Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 59 Years
Sex
All
01

Study summary

To assess the PK and safety after administration of three types of E0302 SR tablets (SR1, SR2, SR3) and E0302 IR tablet.

02

Conditions studied

  • Healthy Subjects

Keywords

  • E0302
  • Healthy Subjects
  • E0302 SR Tablet
  • E0302 IR Tablet
03

In context

Lead sponsor

Eisai Co., Ltd. is the lead sponsor of 152 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 59 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants must meet all of the following criteria to be included in this study:

  1. (BMI) of 18 to 30 kilogram per meter square [kg/m2], inclusive at Screening

Exclusion criteria

Exclusion Criteria:

Participants who meet any of the following criteria will be excluded from this study:

  1. History of drug or alcohol dependency or abuse within the 2 years before Screening, or those who have a positive urine drug test or breath alcohol test at Screening or Baseline
  2. Subjects who contravene the restrictions on concomitant medications, food and beverages
  3. Currently enrolled in another clinical study or used any drug or device within 3 months preceding
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Cohort 1: E0302 Sustained Release (SR1) 1500 mcg

    Participants will receive a single dose of E0302 SR1 1500 microgram (mcg), tablet, orally on Day 1.

    Drug: E0302 SR1

  • Experimental
    Cohort 2: E0302 Sustained Release (SR3) 1500 mcg

    Participants will receive a single dose of E0302 SR3 1500 mcg, tablet on Day 1.

    Drug: E0302 SR3

  • Experimental
    Cohort 3: E0302 SR2 1500 mcg + E0302 IR 500 mcg

    Participants will receive a single dose of E0302 SR2 1500 mcg tablet (Treatment A) on Day 1 in Treatment Period 1 followed by single dose of E0302 IR 500 mcg tablet (Treatment B) on Day 7 in Treatment Period 2. A wash-out phase of at least 5 days will be maintained between the treatment periods.

    Drug: E0302 SR2 · Drug: E0302 IR

  • Experimental
    Cohort 3: E0302 IR 500 mcg + E0302 SR2 500 mcg

    Participants will receive a single dose of E0302 IR 500 mcg tablet (Treatment B) on Day 1 in Treatment Period 1 followed by single dose of E0302 SR2 1500 mcg tablet (Treatment A) on Day 7 in Treatment Period 2. A wash-out phase of at least 5 days will be maintained between the treatment periods.

    Drug: E0302 SR2 · Drug: E0302 IR

Interventions

  • DrugE0302 SR1

    E0302 SR1, oral tablet.

  • DrugE0302 SR3

    E0302 SR3, oral tablet.

  • DrugE0302 SR2

    E0302 SR2, oral tablet.

  • DrugE0302 IR

    E0302 IR, oral tablet.

06

What researchers measure

Primary outcomes

  1. Cmax: Maximum Observed Plasma Concentration for E0302 SR1, SR2, SR3 and IR

    Time frame: Cohort 1 and 2 Day 1: 0-72 hours post dose; Cohort 3 Day 1 or 7: 0-72 hours post dose

  2. AUC (0-t): Area Under the Concentration-Time Curve From Zero Time to Time of Last Quantifiable Concentration

    Time frame: Cohort 1 and 2 Day 1: 0-72 hours post dose, Cohort 3 Day 1 or 7: 0-72 hours post dose

  3. AUC (0 - infinity): Area Under the Concentration-Time Curve From Zero Time Extrapolated to Infinite Time

    Time frame: Cohort 1 and 2 Day 1: 0-72 hours post dose, Cohort 3 Day 1 or 7: 0-72 hours post dose

  4. Number of Participants With Serious Adverse Events (SAEs) and Non-Serious Adverse Events (Non-SAEs)

    Time frame: Cohort 1 and Cohort 2: Up to 12 days, Cohort 3: Up to 18 days

  5. Number of Participants With Abnormal Clinical Laboratory Values

    Time frame: Cohort 1 and Cohort 2: Up to Day 4, Cohort 3: Up to Day 10

  6. Number of Participants With Abnormal Vital Sign Values

    Time frame: Cohort 1 and Cohort 2: Up to Day 2, Cohort 3: Up to Day 8

  7. Number of Participants With Abnormal 12-lead Electrocardiogram Values

    Time frame: Cohort 1 and Cohort 2: Up to Day 12, Cohort 3: Up to Day 18

07

Study locations

1 site
  • Auckland Clinical Studies
    Auckland, New Zealand
08

References and documents

Individual participant data

Plan to share: Yes — Eisai's data sharing commitment and further information on how to request data can be found on our website http://eisaiclinicaltrials.com/.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2019 to primary completion in Jun 2019, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2019
First posted
Mar 22, 2019
StartActual
Apr 13, 2019
Primary completionActual
Jun 26, 2019
CompletionActual
Jun 26, 2019
Last update
Dec 24, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 24, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03885882
Lead sponsor
Eisai Co., Ltd.
Responsible party
Sponsor
First posted
Mar 22, 2019
Start date
Apr 13, 2019
Primary completion
Jun 26, 2019
Completion
Jun 26, 2019
Last update
Dec 24, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion